Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (11-20 of 404) with videos related to

Pageof 41
Sort By:
Continuum (Minneapolis, Minn.)|December 5, 2017
High-grade GliomasLakshmi Nayak, David A Reardon
Seminars in Neurology|March 17, 2018
Concepts for Immunotherapies in GliomasMichael Platten, David A Reardon
Genes & Cancer|August 7, 2012
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignanciesDavid A Reardon, David Cheresh
Current Opinion in Neurology|October 15, 2014
The future of antiangiogenic treatment in glioblastomaOliver L Chinot, David A Reardon
The Oncologist|February 16, 2006
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agentsDavid A Reardon, Patrick Y Wen
Neurosurgery Clinics of North America|March 30, 2021
The Current Landscape of Immune Checkpoint Blockade in GlioblastomaOluwatosin O Akintola, David A Reardon
Nature Reviews. Clinical Oncology|July 17, 2023
A new era for glioma therapy - targeting mutant IDHDavid A Reardon, Daniel P Cahill
Current Opinion in Neurology|November 11, 2022
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trialsBrian M Andersen, David A Reardon
Immunotherapy|June 24, 2015
Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?Martha R Neagu, David A Reardon
Current Treatment Options in Oncology|October 12, 2015
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain TumorsMartha R Neagu, David A Reardon
Pageof 41

Showing results (11-20 of 404) with videos related to

Sort By:
Pageof 41
Continuum (Minneapolis, Minn.)|December 5, 2017
High-grade GliomasLakshmi Nayak, David A Reardon
Seminars in Neurology|March 17, 2018
Concepts for Immunotherapies in GliomasMichael Platten, David A Reardon
Genes & Cancer|August 7, 2012
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignanciesDavid A Reardon, David Cheresh
Current Opinion in Neurology|October 15, 2014
The future of antiangiogenic treatment in glioblastomaOliver L Chinot, David A Reardon
The Oncologist|February 16, 2006
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agentsDavid A Reardon, Patrick Y Wen
Neurosurgery Clinics of North America|March 30, 2021
The Current Landscape of Immune Checkpoint Blockade in GlioblastomaOluwatosin O Akintola, David A Reardon
Nature Reviews. Clinical Oncology|July 17, 2023
A new era for glioma therapy - targeting mutant IDHDavid A Reardon, Daniel P Cahill
Current Opinion in Neurology|November 11, 2022
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trialsBrian M Andersen, David A Reardon
Immunotherapy|June 24, 2015
Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?Martha R Neagu, David A Reardon
Current Treatment Options in Oncology|October 12, 2015
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain TumorsMartha R Neagu, David A Reardon
Pageof 41